Toxicity and Safety Remarks On Cebranopadol: A New Dual-Acting Opioid

Abstract

Introduction: Pain is an aversive sensory experience signaling potential tissue damage, and when chronic, it significantly impairs quality of life and burdens healthcare systems (Smith et al., 2023). Although opioids such as morphine and fentanyl remain effective for severe pain, their use is constrained by tolerance, dependence, and respiratory depression (Wang et al., 2024). Cebranopadol, a first-in-class analgesic, combines activity at classical opioid receptors and nociceptin/orphanin FQ peptide receptors (Christoph et al., 2017), a dual mechanism that may sustain potent analgesia with fewer opioid-related adverse effects (Wang et al., 2024).

Objectives: The present work aims to provide a narrative review of current preclinical and clinical evidence on cebranopadol, with an emphasis on its pharmacological characteristics and toxicological profile.

Results: Evidence shows strong antinociceptive, antiallodynic, and antihyperalgesic activity in acute, inflammatory, and neuropathic pain models (Christoph et al., 2017). Cebranopadol exhibits ~40% oral bioavailability, indicating notable hepatic metabolism (Christoph et al., 2017). In vitro data suggest a low risk of drug–drug interactions despite CYP involvement (Schunk et al., 2014). Clinical trials report significant pain reduction with once-daily dosing, though nausea, dizziness, and headache occur more frequently during titration, and abuse potential at higher doses remains a concern (Smith et al., 2023).

Conclusions: Currently in phase III development and granted FDA fast-track designation, cebranopadol shows promise as a next-generation analgesic. Further studies are necessary to confirm its long-term safety and efficacy.